FDA OKs Burosumab for Rare Form of Rickets
The serious condition leaves children with bowed legs, short stature, and bone and dental pain.
The US FDA this week approved burosumab (Crysvita, Ultragenyx) as the first treatment for x-linked hypophosphatemia (XLH) in adults and children ages 1 and older.
The serious condition leaves children with bowed legs, short stature, and bone and dental pain. Adults with XLH may experience joint pain, impaired mobility, tooth abscesses, and hearing loss. Adults with XLH are also at greater risk of bone fractures. In the United States, XLH affects an estimated 3000 children and 12,000 adults.
This article originally appeared on
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
Effectively Managing Immunizations in the Long-Term Care SettingSeptember 18th 2025
Creating a Culture of Quality in Fast-Melt Tablet DevelopmentSeptember 18th 2025
Advise Patients About Self-Care Measures to Treat Mild to Moderate GI IssuesSeptember 18th 2025
